Genetic association and identification of a functional SNP at GSK3β for schizophrenia susceptibility

Schizophrenia Research

Volumn 133, Issue 1-3, 2011, Pages 165-171

  Li, Ming ^a,e   Mo, Yin ^b   Luo, Xiong jian ^a,e   Xiao, Xiao ^a   Shi, Lei ^a,e   Peng, Ying mei ^a,e   Qi, Xue bin ^a   Liu, Xing yan ^c   Yin, Li de ^c   Diao, Hong bo ^d   Su, Bing ^a  

^a KUNMING INSTITUTE OF ZOOLOGY   (China)

^b KUNMING MEDICAL UNIVERSITY   (China)

^c Second People's Hospital of Yuxi City   (China)

^d Yunnan Mental Health Hospital   (China)

^e UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

Association; EMSA; GSK3 ; Han Chinese; Reporter gene assay; Schizophrenia

Indexed keywords

TRANSCRIPTION FACTOR;

ADULT; ARTICLE; BINDING AFFINITY; CASE CONTROL STUDY; CHINA; CHINESE; CONTROLLED STUDY; GEL MOBILITY SHIFT ASSAY; GENE; GENE FREQUENCY; GENE LOCATION; GENETIC ASSOCIATION; GENETIC IDENTIFICATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; GSK3BETA GENE; HAN CHINESE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; POPULATION RESEARCH; PRIORITY JOURNAL; PROMOTER REGION; RECESSIVE GENE; REPORTER GENE; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; CELL LINE, TRANSFORMED; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; SCHIZOPHRENIA; TRANSFECTION;

EID: 81955164238     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2011.09.013     Document Type: Article

References (36)

1. Badenhop R.F., Moses M.J., Scimone A., Mitchell P.B., Ewen-White K.R., Rosso A., Donald J.A., Adams L.J., Schofield P.R. A genome screen of 13 bipolar affective disorder pedigrees provides evidence for susceptibility loci on chromosome 3 as well as chromosomes 9, 13 and 19. Mol. Psychiatry 2002, 7:851-859.
2. Barrett J.C., Fry B., Maller J., Daly M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005, 21:263-265.
3. Beasley C., Cotter D., Khan N., Pollard C., Sheppard P., Varndell I., Lovestone S., Anderton B., Everall I. Glycogen synthase kinase-3beta immunoreactivity is reduced in the prefrontal cortex in schizophrenia. Neurosci. Lett. 2001, 302:117-120.
4. Cohen J. Statistical power analysis for the behavioral sciences 1988, Lawrence Erlbaum Associates. 2nd ed.
5. Cotter D., Kerwin R., al-Sarraji S., Brion J.P., Chadwich A., Lovestone S., Anderton B., Everall I. Abnormalities of Wnt signalling in schizophrenia--evidence for neurodevelopmental abnormality. Neuroreport 1998, 9:1379-1383.
6. Cui D.H., Jiang K.D., Jiang S.D., Xu Y.F., Yao H. The tumor suppressor adenomatous polyposis coli gene is associated with susceptibility to schizophrenia. Mol. Psychiatry 2005, 10:669-677.
7. Emamian E.S., Hall D., Birnbaum M.J., Karayiorgou M., Gogos J.A. Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat. Genet. 2004, 36:131-137.
8. Fatemi S.H., Folsom T.D. The neurodevelopmental hypothesis of schizophrenia, revisited. Schizophr. Bull. 2009, 35:528-548.
9. Faul F., Erdfelder E., Lang A.G., Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav. Res. Methods 2007, 39:175-191.
10. Hur E.M., Zhou F.Q. GSK3 signalling in neural development. Nat. Rev. Neurosci. 2010, 11:539-551.
11. Ikeda M., Iwata N., Suzuki T., Kitajima T., Yamanouchi Y., Kinoshita Y., Ozaki N. No association of GSK3beta gene (GSK3B) with Japanese schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2005, 134B:90-92.
12. Kim W.Y., Wang X., Wu Y., Doble B.W., Patel S., Woodgett J.R., Snider W.D. GSK-3 is a master regulator of neural progenitor homeostasis. Nat. Neurosci. 2009, 12:1390-1397.
13. Kozlovsky N., Belmaker R.H., Agam G. Low GSK-3beta immunoreactivity in postmortem frontal cortex of schizophrenic patients. Am. J. Psychiatry 2000, 157:831-833.
14. Kozlovsky N., Belmaker R.H., Agam G. Low GSK-3 activity in frontal cortex of schizophrenic patients. Schizophr. Res. 2001, 52:101-105.
15. Kozlovsky N., Shanon-Weickert C., Tomaskovic-Crook E., Kleinman J.E., Belmaker R.H., Agam G. Reduced GSK-3beta mRNA levels in postmortem dorsolateral prefrontal cortex of schizophrenic patients. J. Neural Transm. 2004, 111:1583-1592.
16. Kozlovsky N., Nadri C., Agam G. Low GSK-3beta in schizophrenia as a consequence of neurodevelopmental insult. Eur. Neuropsychopharmacol. 2005, 15:1-11.
17. Kwok J.B., Hallupp M., Loy C.T., Chan D.K., Woo J., Mellick G.D., Buchanan D.D., Silburn P.A., Halliday G.M., Schofield P.R. GSK3B polymorphisms alter transcription and splicing in Parkinson's disease. Ann. Neurol. 2005, 58:829-839.
18. Lee K.Y., Ahn Y.M., Joo E.J., Jeong S.H., Chang J.S., Kim S.C., Kim Y.S. No association of two common SNPs at position -1727 A/T, -50 C/T of GSK-3 beta polymorphisms with schizophrenia and bipolar disorder of Korean population. Neurosci. Lett. 2006, 395:175-178.
19. Li J., Zhou G., Ji W., Feng G., Zhao Q., Liu J., Li T., Li Y., Chen P., Zeng Z., Wang T., Hu Z., Zheng L., Wang Y., Shen Y., He L., Shi Y. Common variants in the BCL9 gene conferring risk of schizophrenia. Arch. Gen. Psychiatry 2011, 68:232-240.
20. Lie D.C., Colamarino S.A., Song H.J., Desire L., Mira H., Consiglio A., Lein E.S., Jessberger S., Lansford H., Dearie A.R., Gage F.H. Wnt signalling regulates adult hippocampal neurogenesis. Nature 2005, 437:1370-1375.
21. Luo X.J., Diao H.B., Wang J.K., Zhang H., Zhao Z.M., Su B. Association of haplotypes spanning PDZ-GEF2, LOC728637 and ACSL6 with schizophrenia in Han Chinese. J. Med. Genet. 2008, 45:818-826.
22. Mao Y., Ge X., Frank C.L., Madison J.M., Koehler A.N., Doud M.K., Tassa C., Berry E.M., Soda T., Singh K.K., Biechele T., Petryshen T.L., Moon R.T., Haggarty S.J., Tsai L.H. Disrupted in schizophrenia 1 regulates neuronal progenitor proliferation via modulation of GSK3beta/beta-catenin signaling. Cell 2009, 136:1017-1031.
23. Meng J., Shi Y., Zhao X., Zhou J., Zheng Y., Tang R., Ma G., Zhu X., He Z., Wang Z., Xu Y., Feng G., He L. No significant association between the genetic polymorphisms in the GSK-3 beta gene and schizophrenia in the Chinese population. J. Psychiatr. Res. 2008, 42:365-370.
24. Mueser K.T., McGurk S.R. Schizophrenia. Lancet 2004, 363:2063-2072.
25. Nadri C., Dean B., Scarr E., Agam G. GSK-3 parameters in postmortem frontal cortex and hippocampus of schizophrenic patients. Schizophr. Res. 2004, 71:377-382.
26. Prickaerts J., Moechars D., Cryns K., Lenaerts I., van Craenendonck H., Goris I., Daneels G., Bouwknecht J.A., Steckler T. Transgenic mice overexpressing glycogen synthase kinase 3beta: a putative model of hyperactivity and mania. J. Neurosci. 2006, 26:9022-9029.
27. Proitsi P., Li T., Hamilton G., Di Forti M., Collier D., Killick R., Chen R., Sham P., Murray R., Powell J., Lovestone S. Positional pathway screen of wnt signaling genes in schizophrenia: association with DKK4. Biol. Psychiatry 2008, 63:13-16.
28. Purcell S., Neale B., Todd-Brown K., Thomas L., Ferreira M.A., Bender D., Maller J., Sklar P., de Bakker P.I., Daly M.J., Sham P.C. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 2007, 81:559-575.
29. Scassellati C., Bonvicini C., Perez J., Bocchio-Chiavetto L., Tura G.B., Rossi G., Racagni G., Gennarelli M. Association study of -1727 A/T, -50 C/T and (CAA)n repeat GSK-3beta gene polymorphisms with schizophrenia. Neuropsychobiology 2004, 50:16-20.
30. Schaid D.J., Rowland C.M., Tines D.E., Jacobson R.M., Poland G.A. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am. J. Hum. Genet. 2002, 70:425-434.
31. Souza R.P., Romano-Silva M.A., Lieberman J.A., Meltzer H.Y., Wong A.H., Kennedy J.L. Association study of GSK3 gene polymorphisms with schizophrenia and clozapine response. Psychopharmacology (Berl) 2008, 200:177-186.
32. Spittaels K., Van den Haute C., Van Dorpe J., Terwel D., Vandezande K., Lasrado R., Bruynseels K., Irizarry M., Verhoye M., Van Lint J., Vandenheede J.R., Ashton D., Mercken M., Loos R., Hyman B., Van der Linden A., Geerts H., Van Leuven F. Neonatal neuronal overexpression of glycogen synthase kinase-3 beta reduces brain size in transgenic mice. Neuroscience 2002, 113:797-808.
33. Steen R.G., Mull C., McClure R., Hamer R.M., Lieberman J.A. Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies. Br. J. Psychiatry 2006, 188:510-518.
34. Szczepankiewicz A., Skibinska M., Hauser J., Slopien A., Leszczynska-Rodziewicz A., Kapelski P., Dmitrzak-Weglarz M., Czerski P.M., Rybakowski J.K. Association analysis of the GSK-3beta T-50C gene polymorphism with schizophrenia and bipolar disorder. Neuropsychobiology 2006, 53:51-56.
35. Xu M.Q., Xing Q.H., Zheng Y.L., Li S., Gao J.J., He G., Guo T.W., Feng G.Y., Xu F., He L. Association of AKT1 gene polymorphisms with risk of schizophrenia and with response to antipsychotics in the Chinese population. J. Clin. Psychiatry 2007, 68:1358-1367.
36. Yang J., Si T., Ling Y., Ruan Y., Han Y., Wang X., Zhang H., Kong Q., Li X., Liu C., Zhang D., Zhou M., Yu Y., Liu S., Shu L., Ma D., Wei J. Association study of the human FZD3 locus with schizophrenia. Biol. Psychiatry 2003, 54:1298-1301.